



## Immunotherapy for Non-small Cell Lung Cancer

Guest Editors:

**Prof. Dr. Ramon Andrade De Mello**

1. Oxford Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK  
2. Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK  
3. Post-Graduation Program in Medicine, Nine of July University, (UNINOVE), São Paulo 01525-001, SP, Brazil

**Prof. Nam P. Nguyen**

Department of Radiation Oncology, Howard University College of Medicine, Washington, DC, USA

### Message from the Guest Editors

Dear Colleagues,

Non-small cell lung cancer (NSCLC) is a disease with high mortality world-wide. However, treatment approaches have been improving in the last few decades. Several immune checkpoints inhibitors acquired an important role in the clinical practice either in the adjuvant or in metastatic setting. Thus, this Special Issue will focus in the basic, translational, and clinical research in the field of immunotherapy in order to understand the future trends in this field.

Prof. Dr. Ramon Andrade De Mello

Prof. Nam P. Nguyen

*Guest Editors*

Deadline for manuscript submissions:

**closed (12 November 2021)**





*cancers*



an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Samuel C. Mok**

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI